Grindeks                                                        15.04.2004.



Information on development of Joint Stock Company "Grindeks" 



JSC Grindeks continues to expand its sphere of activities by developing the 

first pharmaceutical holding company in the Baltic States. New forms of cooperation 

with the other producers of pharmaceuticals in the Baltic States and in the other 

states of Europe are searched for and   new markets for the existing products are 

regularly considered, as well as a possibility for development and promotion of 

new products is reflected on.



In the framework of a long term development strategy, JSC Grindeks develops a net 

of representative offices in new regions and continues to investigate the 

profitability and efficiency of the forms of potential cooperation, considering 

also the possibilities  of purchasing some share capital in other pharmaceutical 

companies.



JSC Grindeks as a potential investor has received an offer to take part in a purchase 

bargain where the State institutions of Poland would sell their stock capital in 

pharmaceutical company Jelfa. Currently JSC Grindeks is considering this proposal 

and in case of any kind of mutual agreement with the Polish pharmaceutical company 

Jelfa   will provide  Riga Stock Exchange with the information  about the status of 

the particular undertaking in compliance with Riga Stock Exchange listing and 

disclosure rules.



As reported before, a successful cooperation with Polish pharmaceuticals manufacturer 

Jelfa has been started in the year 2004 by concluding a contract, the subject of 

which is a contract manufacture of the injections of  Grindeks original product 

Mildronate. 



Information prepared by:

Jānis Romanovskis,

Finance and Administrative director

JSC Grindeks

Tel: 7083250

e-mail: jromanovskis@grindeks.lv